Generex Biotechnology Corp (GNBT) financial statements (2021 and earlier)

Company profile

Business Address 10102 USA TODAY WAY
MIRAMAR, FL 33025
State of Incorp. DE
Fiscal Year End July 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

1/31/2021
TTM
7/31/2020
7/31/2019
7/31/2018
7/31/2017
7/31/2016
7/31/2015
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments1001301
Cash and cash equivalents1001301
Inventory, net of allowances, customer advances and progress billings11000  
Inventory11000  
Intangible current assets      0
Other current assets0000000
Other undisclosed current assets0000  (0)
Total current assets:2111301
Noncurrent Assets
Operating lease, right-of-use asset00 
Property, plant and equipment0000000
Intangible assets, net (including goodwill)37383933 1
Goodwill343438    
Intangible assets, net (excluding goodwill)33133 1
Other undisclosed noncurrent assets66924  
Total noncurrent assets:4444495701
TOTAL ASSETS:46455071002
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including:392419111098
Accounts payable 1   43
Accrued liabilities     00
Employee-related liabilities7    00
Interest and dividends payable 4     
Other undisclosed accounts payable and accrued liabilities321919111054
Deferred revenue3  
Debt1011     
Derivative instruments and hedges, liabilities 1     
Due to related parties0      
Other undisclosed current liabilities751014140 
Total current liabilities:604129252498
Noncurrent Liabilities
Long-term debt and lease obligation10     
Long-term debt, excluding current maturities00     
Operating lease, liability0  
Liabilities, other than long-term debt3218  22
Derivative instruments and hedges, liabilities3218  22
Other undisclosed noncurrent liabilities910(7)256600
Total noncurrent liabilities:41121256623
Other undisclosed liabilities  8    
Total liabilities:101533850901111
Temporary equity, carrying amount444    
Stockholders' equity
Stockholders' equity attributable to parent, including:(59)(12)8(44)(80)(11)(8)
Common stock0000011
Additional paid in capital420430409368368363363
Accumulated other comprehensive income1111111
Accumulated deficit(489)(452)(419)  (376)(372)
Warrants and rights outstanding      2
Stockholders' equity note, subscriptions receivable(0)     
Other undisclosed stockholders' equity attributable to parent9917(413)(449) (2)
Total stockholders' equity:(59)(12)8(44)(80)(11)(8)
TOTAL LIABILITIES AND EQUITY:46455071002

Income statement (P&L) ($ in millions)

1/31/2021
TTM
7/31/2020
7/31/2019
7/31/2018
7/31/2017
7/31/2016
7/31/2015
Revenues(1) 61   
Cost of revenue(0)(1)(4)    
Cost of goods and services sold  (1)    
Other undisclosed gross profit33     
Gross profit:1221   
Operating expenses(32)(20)(26)(3)(2)(2)(4)
Other undisclosed operating loss(0)      
Operating loss:(32)(18)(24)(2)(2)(2)(4)
Nonoperating income
(Investment Income, Nonoperating)
   1  0
Interest and debt expense(5)(7)(7)(1)(1)(0)(0)
Loss before gain (loss) on sale of properties:(36)(25)(31)(2)(2)(2)(4)
Other undisclosed net income      2
Net loss:(36)(25)(31)(2)(2)(2)(2)
Net income attributable to noncontrolling interest11207  
Other undisclosed net income (loss) attributable to parent(18)(10)1938(81)(1) 
Net income (loss) attributable to parent:(53)(34)(11)36(77)(3)(2)
Preferred stock dividends and other adjustments      (0)
Other undisclosed net income available to common stockholders, basic11207  
Net income (loss) available to common stockholders, diluted:(52)(33)(9)36(70)(3)(3)

Comprehensive Income ($ in millions)

1/31/2021
TTM
7/31/2020
7/31/2019
7/31/2018
7/31/2017
7/31/2016
7/31/2015
Net loss:(36)(25)(31)(2)(2)(2)(2)
Comprehensive loss:(36)(25)(31)(2)(2)(2)(2)
Comprehensive income, net of tax, attributable to noncontrolling interest11207  
Other undisclosed comprehensive income, net of tax, attributable to parent      0
Comprehensive income (loss), net of tax, attributable to parent:(35)(24)(30)(2)4(2)(2)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: